Nektar Therapeutics Announces Two Abstracts Accepted At EADV Congress 2023 For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics (NASDAQ:NKTR) announced that it will present two abstracts on rezpegaldesleukin, a first-in-class selective regulatory T-cell therapy, at the 2023 European Academy of Dermatology and Venereology Congress. The presentations will cover Phase 1b safety and efficacy data for rezpegaldesleukin in moderate to severe atopic dermatitis and the design of a Phase 2b study. The company plans to advance the program into a robust Phase 2b study later this month.
October 02, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nektar Therapeutics' announcement of two presentations at the EADV Congress 2023 and the upcoming Phase 2b study for rezpegaldesleukin could potentially boost investor confidence in the company's research and development capabilities.
The announcement of the presentations at a prestigious congress and the upcoming Phase 2b study indicates progress in Nektar's research and development efforts. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100